本文言語 | English |
---|---|
ページ(範囲) | 332-333 |
ページ数 | 2 |
ジャーナル | Journal of Neurogastroenterology and Motility |
巻 | 25 |
号 | 2 |
DOI | |
出版ステータス | Published - 2019 4月 1 |
ASJC Scopus subject areas
- 臨床神経学
- 消化器病学
引用スタイル
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Effect of Mizagliflozin on Postprandial Plasma Glucose in Patients with Functional Constipation. / Fukudo, Shin; Kaku, Kohei.
In: Journal of Neurogastroenterology and Motility, Vol. 25, No. 2, 01.04.2019, p. 332-333.研究成果: Letter › 査読
}
TY - JOUR
T1 - Effect of Mizagliflozin on Postprandial Plasma Glucose in Patients with Functional Constipation
AU - Fukudo, Shin
AU - Kaku, Kohei
N1 - Funding Information: Financial support: This study was funded by Kissei Pharmaceutical Co, Ltd (Grant No. KWA1205). Conflicts of interest: Shin Fukudo reports grants and personal fees from Kissei Pharmaceutical, during the conduct of the study; personal fees from Dainippon Sumitomo Pharma, grants and personal fees from Abott Japan, personal fees from Scampo Pharma, grants from Ono Pharmaceutical, grants and personal fees from Astellas Pharmaceutical, personal fees from Sanwa Chemical Co. Ltd, personal fees from Zeria, personal fees from Glaxo-Smith-Kline, personal fees Funding Information: from Mochida Pharmaceutical, personal fees from Shionogi Pharmaceutical, grants and personal fees from AstraZeneca, grants from Smoking Research Foundation, grants and personal fees from Tsumu-ta Co. Ltd., personal fees and non-financial support from Miyarisan Pharmaceutical, grants from Kao Co. Ltd., and grants from Zespri Co. Ltd, outside the submitted work. Kohei Kaku reports personal fees from Kissei Pharmaceutical, during the conduct of the study; grants and personal fees from Boehringer Ingelheim, grants from Daiichi Sankyo, grants and personal fees from Taisho Toyama Pharmaceutical, grants and personal fees from Mitsubishi Tanabe Pharma, grants and personal fees from Takeda Pharmaceutical, grants and personal fees from Astellas Pharma, personal fees from AstraZeneca, personal fees from Sumitomo Dainippon Pharma, personal fees from Kissei Pharmaceutical, personal fees from Kowa, personal fees from MSD, personal fees from Novartis Pharma, personal fees from Ono Pharmaceutical, and personal fees from Sanofi K.K, outside the submitted work. Author contributions: Shin Fukudo and Kohei Kaku designed, performed, and analysed the study. All authors contributed to data interpretation, writing, and final approval of the manuscript.
PY - 2019/4/1
Y1 - 2019/4/1
UR - http://www.scopus.com/inward/record.url?scp=85113785369&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85113785369&partnerID=8YFLogxK
U2 - 10.5056/JNM19010
DO - 10.5056/JNM19010
M3 - Letter
AN - SCOPUS:85113785369
VL - 25
SP - 332
EP - 333
JO - Journal of Neurogastroenterology and Motility
JF - Journal of Neurogastroenterology and Motility
SN - 2093-0879
IS - 2
ER -